C R Rayner

Summary

Affiliation: Monash University
Country: Australia

Publications

  1. ncbi request reprint Symptomatic hyperbilirubinemia with indinavir/ritonavir-containing regimen
    C R Rayner
    Department of Pharmacy Practice, Monash University, Parkville, Victoria, Australia
    Ann Pharmacother 35:1391-5. 2001
  2. ncbi request reprint A critical evaluation of the therapeutic range of indinavir
    Craig R Rayner
    Department of Pharmacy Practice, Victorian College of Pharmacy, Monash University, Parkville, Australia
    Ann Pharmacother 36:1230-7. 2002
  3. ncbi request reprint Linezolid in the treatment of osteomyelitis: results of compassionate use experience
    C R Rayner
    Facility for Anti Infective Drug Development and Innovation, Victorian College of Pharmacy, Monash University, 381 Royal Parade, 3052, Parkville, Vic, Australia
    Infection 32:8-14. 2004
  4. ncbi request reprint Simple method for the assay of eperezolid in brain heart infusion broth by high-performance liquid chromatography
    Jian Li
    Facility for Anti Infective Drug Development and Innovation, Victorian College of Pharmacy, Monash University, Parkville, VIC 3052, Australia
    J Pharm Biomed Anal 35:847-51. 2004
  5. ncbi request reprint Colistin: the re-emerging antibiotic for multidrug-resistant Gram-negative bacterial infections
    Jian Li
    Facility for Anti Infective Drug Development and Innovation, Victorian College of Pharmacy, Monash University, Parkville, Victoria, Australia
    Lancet Infect Dis 6:589-601. 2006
  6. ncbi request reprint Dosing information for paediatric patients: are they really "therapeutic orphans"?
    Elaine Tan
    Department of Pharmacy Practice, Victorian College of Pharmacy, Monash University, 381 Royal Parade, Parkville, VIC 3052, Australia
    Med J Aust 179:195-8. 2003
  7. pmc Heteroresistance to colistin in multidrug-resistant Acinetobacter baumannii
    Jian Li
    Facility for Anti Infective Drug Development and Innovation, Victorian College of Pharmacy, Monash University, Parkville, Victoria 3052, Australia
    Antimicrob Agents Chemother 50:2946-50. 2006
  8. pmc Colistin methanesulfonate is an inactive prodrug of colistin against Pseudomonas aeruginosa
    Phillip J Bergen
    Facility for Anti Infective Drug Development and Innovation, Victorian College of Pharmacy, Monash University, Parkville, Victoria, Australia
    Antimicrob Agents Chemother 50:1953-8. 2006
  9. pmc Pharmacokinetic/pharmacodynamic factors influencing emergence of resistance to linezolid in an in vitro model
    Lauren M Boak
    Facility for Anti Infective Drug Development and Innovation, Victorian College of Pharmacy, Monash University, 381 Royal Parade, Parkville, Victoria 3052, Australia
    Antimicrob Agents Chemother 51:1287-92. 2007
  10. pmc Elucidation of the pharmacokinetic/pharmacodynamic determinant of colistin activity against Pseudomonas aeruginosa in murine thigh and lung infection models
    Rajesh V Dudhani
    Facility for Anti Infective Drug Development and Innovation, Monash Institute of Pharmaceutical Sciences, Monash University, Melbourne, Australia
    Antimicrob Agents Chemother 54:1117-24. 2010

Collaborators

Detail Information

Publications25

  1. ncbi request reprint Symptomatic hyperbilirubinemia with indinavir/ritonavir-containing regimen
    C R Rayner
    Department of Pharmacy Practice, Monash University, Parkville, Victoria, Australia
    Ann Pharmacother 35:1391-5. 2001
    ..To report a case of symptomatic hyperbilirubinemia resulting from the addition of ritonavir to an indinavir-containing antiretroviral regimen...
  2. ncbi request reprint A critical evaluation of the therapeutic range of indinavir
    Craig R Rayner
    Department of Pharmacy Practice, Victorian College of Pharmacy, Monash University, Parkville, Australia
    Ann Pharmacother 36:1230-7. 2002
    ..To provide a summary of the patient population, study characteristics, and important findings of the key studies in the literature evaluating concentration-effect relationships and the therapeutic range for indinavir...
  3. ncbi request reprint Linezolid in the treatment of osteomyelitis: results of compassionate use experience
    C R Rayner
    Facility for Anti Infective Drug Development and Innovation, Victorian College of Pharmacy, Monash University, 381 Royal Parade, 3052, Parkville, Vic, Australia
    Infection 32:8-14. 2004
    ..This case series examines osteomyelitis patients enrolled into a prospective, open label, noncomparative, non-randomized compassionate use program. Patients received 600 mg bid iv or po linezolid...
  4. ncbi request reprint Simple method for the assay of eperezolid in brain heart infusion broth by high-performance liquid chromatography
    Jian Li
    Facility for Anti Infective Drug Development and Innovation, Victorian College of Pharmacy, Monash University, Parkville, VIC 3052, Australia
    J Pharm Biomed Anal 35:847-51. 2004
    ..The intra- and inter-day accuracy and reproducibility (relative standard deviation, R.S.D.) were less than 12.3%. This assay is rapid and ideal for analysis of a large number of samples...
  5. ncbi request reprint Colistin: the re-emerging antibiotic for multidrug-resistant Gram-negative bacterial infections
    Jian Li
    Facility for Anti Infective Drug Development and Innovation, Victorian College of Pharmacy, Monash University, Parkville, Victoria, Australia
    Lancet Infect Dis 6:589-601. 2006
    ..In the battle against rapidly emerging bacterial resistance we can no longer rely entirely on the discovery of new antibiotics; we must also pursue rational approaches to the use of older antibiotics such as colistin...
  6. ncbi request reprint Dosing information for paediatric patients: are they really "therapeutic orphans"?
    Elaine Tan
    Department of Pharmacy Practice, Victorian College of Pharmacy, Monash University, 381 Royal Parade, Parkville, VIC 3052, Australia
    Med J Aust 179:195-8. 2003
    ..To review the approved product information (PI) of prescription medicines to determine the extent and nature of information available on paediatric dosing and the availability of paediatric dosage formulations in Australia...
  7. pmc Heteroresistance to colistin in multidrug-resistant Acinetobacter baumannii
    Jian Li
    Facility for Anti Infective Drug Development and Innovation, Victorian College of Pharmacy, Monash University, Parkville, Victoria 3052, Australia
    Antimicrob Agents Chemother 50:2946-50. 2006
    ..Our findings give a strong warning that colistin-resistant A. baumannii may be observed more frequently due to potential suboptimal dosage regimens recommended in the product information of some products of colistin methanesulfonate...
  8. pmc Colistin methanesulfonate is an inactive prodrug of colistin against Pseudomonas aeruginosa
    Phillip J Bergen
    Facility for Anti Infective Drug Development and Innovation, Victorian College of Pharmacy, Monash University, Parkville, Victoria, Australia
    Antimicrob Agents Chemother 50:1953-8. 2006
    ..These findings have important implications for susceptibility testing involving "colistin," in particular, for MIC measurement and for microbiological assays and pharmacokinetic and pharmacodynamic studies...
  9. pmc Pharmacokinetic/pharmacodynamic factors influencing emergence of resistance to linezolid in an in vitro model
    Lauren M Boak
    Facility for Anti Infective Drug Development and Innovation, Victorian College of Pharmacy, Monash University, 381 Royal Parade, Parkville, Victoria 3052, Australia
    Antimicrob Agents Chemother 51:1287-92. 2007
    ..The potential for resistance development appears to be higher when a constant concentration is maintained in the vicinity of the MIC of the bacteria...
  10. pmc Elucidation of the pharmacokinetic/pharmacodynamic determinant of colistin activity against Pseudomonas aeruginosa in murine thigh and lung infection models
    Rajesh V Dudhani
    Facility for Anti Infective Drug Development and Innovation, Monash Institute of Pharmaceutical Sciences, Monash University, Melbourne, Australia
    Antimicrob Agents Chemother 54:1117-24. 2010
    ..The findings of this in vivo study indicate the importance of achieving adequate time-averaged exposure to colistin. The results will facilitate efforts to define the more rational design of dosage regimens for humans...
  11. ncbi request reprint Simple method for the assay of linezolid in Brain Heart Infusion broth by high-performance liquid chromatography
    Jian Li
    Department of Pharmacy Practice, Victorian College of Pharmacy, Monash University, Parkville, Victoria 3052, Australia
    Biomed Chromatogr 18:1-5. 2004
    ..Linezolid was stable in the autosampler insert for at least 24 h at ambient temperature and in BHI for 72 h at 37 degrees C. This assay is rapid and ideal for analysis of a large number of samples...
  12. ncbi request reprint Clinical pharmacodynamics of linezolid in seriously ill patients treated in a compassionate use programme
    Craig R Rayner
    Department of Pharmacy Practice, Victorian College of Pharmacy, Monash University, Parkville, Victoria, Australia
    Clin Pharmacokinet 42:1411-23. 2003
    ..To characterise the pharmacokinetic-pharmacodynamic relationships for linezolid efficacy...
  13. pmc Differential bidirectional transfer of indinavir in the isolated perfused human placenta
    Sreeja Sudhakaran
    Facility for Anti Infective Drug Development and Innovation, Monash University, 381 Royal Parade, Parkville, 3052, Melbourne, Australia
    Antimicrob Agents Chemother 49:1023-8. 2005
    ..The use of transport modulators to increase the maternal-to-fetal transfer of PIs as a possible strategy to reduce mother-to-child transmission of HIV warrants investigation...
  14. ncbi request reprint High-performance liquid chromatographic method for simple and rapid determination of linezolid in human plasma
    Lauren M Boak
    Facility for Anti Infective Drug Development and Innovation, Department of Pharmacy Practice, Victorian College of Pharmacy, Monash University, Parkville, Victoria 3052, Australia
    Biomed Chromatogr 20:782-6. 2006
    ..Overall, this assay offers a highly simplistic approach to quantifying linezolid in plasma, and would be well suited to clinical pharmacokinetic, pharmacodynamic and toxicodynamic analyses...
  15. pmc Stability of colistin methanesulfonate in pharmaceutical products and solutions for administration to patients
    Stephanie J Wallace
    Facility for Anti Infective Drug Development and Innovation, Drug Delivery, Disposition and Dynamics, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Melbourne, Victoria, Australia
    Antimicrob Agents Chemother 52:3047-51. 2008
    ..1%). This study demonstrated the concentration- and temperature-dependent hydrolysis of CMS. The information provided by this study has important implications for the formulation and clinical use of CMS products...
  16. pmc Inhibition of placental P-glycoprotein: impact on indinavir transfer to the foetus
    Sreeja Sudhakaran
    Facility for Anti Infective Drug Development and Innovation, Monash University, Parkville, 3052, Melbourne, Australia
    Br J Clin Pharmacol 65:667-73. 2008
    ..The efflux transporter P-gp located in the apical membrane domain of the placental trophoblast cells has been implicated as the likely cause of the differential bi-directional transport...
  17. pmc Subacute toxicity of colistin methanesulfonate in rats: comparison of various intravenous dosage regimens
    Stephanie J Wallace
    Facility for Anti Infective Drug Development and Innovation, Victorian College of Pharmacy, Monash University, 381 Royal Parade, Parkville, Victoria 3052, Australia
    Antimicrob Agents Chemother 52:1159-61. 2008
    ..Histological examination revealed more-severe renal lesions with the regimen corresponding to once-daily dosing, indicating that the potential for renal toxicity may be greater with extended-interval dosing...
  18. pmc Differential protein binding of indinavir and saquinavir in matched maternal and umbilical cord plasma
    Sreeja Sudhakaran
    Facility for Anti Infective Drug Development and Innovation, Monash University, Melbourne, Australia
    Br J Clin Pharmacol 63:315-21. 2007
    ..To determine whether lower umbilical cord than maternal binding of indinavir and saquinavir contributed to the low cord : maternal (C : M) total concentration ratios reported previously...
  19. ncbi request reprint Successful treatment and cerebrospinal fluid penetration of oral linezolid in a patient with coagulase-negative Staphylococcus ventriculitis
    Lauren M Boak
    Facility for Anti Infective Drug Development and Innovation, Department of Pharmacy Practice, Victorian College of Pharmacy, Monash University, Parkville, Australia
    Ann Pharmacother 40:1451-5. 2006
    ..To describe a case of coagulase-negative Staphylococcus ventriculitis successfully treated with oral linezolid, for which good cerebrospinal fluid (CSF) penetration was observed...
  20. ncbi request reprint Multidisciplinary HIV adherence intervention: a randomized study
    R W Levy
    Department of Pharmacy, The Alfred, Victoria, Australia
    AIDS Patient Care STDS 18:728-35. 2004
    ..9 to 1.0, p < 0.001), 7 (3.0 to 1.8, p < 0.001) and 28 (7.4 to 4.2, p < 0.001) days and a decrease in the Morisky score, indicating an improvement in medication taking behaviour (1.3 to 0.5 p < 0.001)...
  21. ncbi request reprint Linezolid for the treatment of multidrug-resistant, gram-positive infections: experience from a compassionate-use program
    Mary C Birmingham
    CPL Associates, University at Buffalo, New York, USA
    Clin Infect Dis 36:159-68. 2003
    ..1% of cases), and cutaneous reactions (4.0% of cases). Linezolid provided high rates of clinical cure and microbiological success in this complicated patient population, with very good overall tolerance...
  22. pmc Population pharmacokinetics of linezolid in patients treated in a compassionate-use program
    Alison K Meagher
    CPL Associates, LLC, Amherst, New York, USA
    Antimicrob Agents Chemother 47:548-53. 2003
    ..The mechanism(s) of these pharmacokinetic differences is unknown and requires further mechanistic study...
  23. ncbi request reprint Similarity in pharmacokinetics of oseltamivir and oseltamivir carboxylate in Japanese and Caucasian subjects
    Jerome J Schentag
    University at Buffalo School of Pharmacy, 517 Hochstetter Hall, Buffalo, NY 14260, USA
    J Clin Pharmacol 47:689-96. 2007
    ..In conclusion, the results of this study support the use of the same dose regimens of oseltamivir in both Caucasian and Japanese subjects because of similarity in pharmacokinetics...
  24. doi request reprint Population pharmacokinetics of oseltamivir when coadministered with probenecid
    Craig R Rayner
    F Hoffmann La Roche Ltd, Pharmaceuticals Division, Bldg 015 1 006, CH 4070 Basel, Switzerland
    J Clin Pharmacol 48:935-47. 2008
    ..These factors, set alongside increased capacity for oseltamivir production, should be carefully considered before an oseltamivir-probenecid combination is used...
  25. ncbi request reprint Colistin-associated acute renal failure: revisited
    Jian Li
    South Med J 98:1229-30. 2005